Trial site landscapes

Public-registry site landscapes for recently registered and scanned clinical trials: listed sites, countries, and recruiting-density context, compiled from ClinicalTrials.gov. The 100 most recent are listed here; any covered trial is at /trials/<NCT id>.

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories
NCT04469686 — Cristcot LLC, Ulcerative Proctitis

NCT04380805
NCT04380805 — Akeso, Recurrent Cervical Cancer

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
NCT04844983 — Sirnaomics, Squamous Cell Carcinoma in Situ

NCT03983395
NCT03983395 — Ichnos Sciences SA, Breast Cancer

NCT05307328
NCT05307328 — Sparrow Pharmaceuticals, Cushing's Syndrome I

NCT05759208
NCT05759208 — Okyo Pharma Ltd, Dry Eye Disease

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
NCT03821038 — Revimmune, Sepsis, Severe

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
NCT03795428 — PhaseBio Pharmaceuticals Inc., Pulmonary Arterial Hypertension

Study to Evaluate MET642 in Patients With NASH
NCT04773964 — Metacrine, Inc., NASH - Nonalcoholic Steatohepatitis

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04516096 — Amylyx Pharmaceuticals Inc., Amyotrophic Lateral Sclerosis

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270 — Jacobio Pharmaceuticals Co., Ltd., Advanced Solid Tumor

NCT03630939
NCT03630939 — Escalier Biosciences B.V., Psoriatic Plaque

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
NCT02656394 — Glia, LLC, Ocular Surface Disease

NCT05730218
NCT05730218 — ONL Therapeutics, Rhegmatogenous Retinal Detachment - Macula Off

Method Comparison of Intelligent Fingerprinting Drug Screening System
NCT07650136 — Intelligent Bio Solutions Inc., Drug Abuse Illicit

NCT07743164
NCT07743164 — Merck Sharp & Dohme LLC, Ovarian Cancer

NCT07742280
NCT07742280 — Bostal Drug Delivery Co., Ltd, Schizophrenia

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 — Ascletis Pharma (China) Co., Limited, Obesity or Overweight With Type 2 Diabetes Mellitus

NCT07743112
NCT07743112 — Maxinovel Pty., Ltd., Acute Myeloid Leukemia

NCT07740733
NCT07740733 — Beijing Minhai Biotechnology Co., Ltd, Tetanus

A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
NCT07742098 — NeuroTrauma Sciences, LLC, Acute Ischemic Stroke

A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
NCT07740720 — GlaxoSmithKline, Neoplasms, Rectal

Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
NCT07743008 — InventVacc Biologicals Inc., Haemophilus Influenzae

NCT07741045
NCT07741045 — Hangzhou PhecdaMed Co., Ltd., Parkinson's Disease (PD)

NCT07741526
NCT07741526 — Arctic Therapeutics, Alzheimer´s Disease

NCT07741240
NCT07741240 — Chengdu Kanghong Pharmaceutical Group Co., Ltd., Major Depressive Disorder (MDD)

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463 — Ascletis Pharma (China) Co., Limited, Obesity or Overweight With Weight-Related Comorbidities

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735 — VectivBio AG, Short Bowel Syndrome (SBS)

NCT07742852
NCT07742852 — Jiangsu Aosaikang Pharmaceutical Co., Ltd., Osteoarthritis (OA) of the Knee

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder
NCT07741331 — Chengdu Kanghong Pharmaceutical Group Co., Ltd., Major Depressive Disorder (MDD)

NCT07742215
NCT07742215 — Biocad, Myeloma Multiple

NCT07742644
NCT07742644 — GlaxoSmithKline, Measles

NCT07742956
NCT07742956 — Shanghai Allink Biotherapeutics Co., Ltd., NSCLC (Advanced Non-small Cell Lung Cancer)

NCT07741877
NCT07741877 — Iovance Biotherapeutics, Inc., Sarcoma

NCT04722887
NCT04722887 — Grifols Therapeutics LLC, Alpha1-Antitrypsin Deficiency

NCT06974916
NCT06974916 — InSightec, Essential Tremor

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877 — Ventus Therapeutics U.S., Inc., Cutaneous Lupus Erythematosus (CLE)

NCT07361276
NCT07361276 — AstraZeneca, Hypertension

NCT05045482
NCT05045482 — Zydus Therapeutics Inc., Hepatic Impairment

Clinical Evaluation of Visby Medical Men's Sexual Health Test
NCT07659808 — Visby Medical, Sexually Transmitted Diseases

NCT07607483
NCT07607483 — Eli Lilly and Company, Healthy

NCT05802329
NCT05802329 — Ocugen, Center Involved Diabetic Macular Edema

NCT06825559
NCT06825559 — Zydus Therapeutics Inc., Cholestatic Liver Disease

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379
NCT07712718 — Mirum Pharmaceuticals, Inc., Healthy Volunteers

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
NCT07413757 — AstraZeneca, Non-Small Cell Lung Cancer

NCT06828848
NCT06828848 — Menarini Group, Gram Negative Infections

NCT07191704
NCT07191704 — Ipsen, PFIC - Progressive Familial Intrahepatic Cholestasis

NCT02251067
NCT02251067 — Vascular Pharmaceuticals, Inc., Diabetic Nephropathy

NCT01066702
NCT01066702 — Histogenics Corporation, Articular Cartilage Defects in the Knee Joint

NCT03363945
NCT03363945 — Medeor Therapeutics, Inc., Kidney Transplant Rejection

NCT04906694
NCT04906694 — Sorrento Therapeutics, Inc., Covid19

NCT04033575
NCT04033575 — Colgate Palmolive, Gingivitis

NCT03639883
NCT03639883 — AiViva BioPharma, Inc., Scar

NCT02481674
NCT02481674 — Vaccinex Inc., Huntington's Disease

NCT04388904
NCT04388904 — The Crofoot Research Center, Inc., HIV-1-infection

NCT03382977
NCT03382977 — VBI Vaccines Inc., Glioblastoma Multiforme

NCT04387461
NCT04387461 — CG Oncology, Inc., Non Muscle Invasive Bladder Cancer

NCT01393223
NCT01393223 — Lipella Pharmaceuticals, Inc., Interstitial Cystitis

NCT03101163
NCT03101163 — KLSMC Stem Cells, Inc., Articular Cartilage Disorder of Knee

NCT05709444
NCT05709444 — Palatin Technologies, Inc, Kidney Disease

NCT03837457
NCT03837457 — miRagen Therapeutics, Inc., Cutaneous T-Cell Lymphoma/Mycosis Fungoides

NCT04996875
NCT04996875 — Cogent Biosciences, Inc., Advanced Systemic Mastocytosis (AdvSM)

NCT07739966
NCT07739966 — Daiichi Sankyo, Solid Tumor

NCT07739758
NCT07739758 — MediLink Therapeutics (Suzhou) Co., Ltd., SCLC, Extensive Stage

NCT07738198
NCT07738198 — Colgate Palmolive, Dental Hypersensitivity

NCT07740421
NCT07740421 — Trust Bio-sonics, Inc., Cardiac Diseases

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
NCT07740564 — Ocumension Therapeutics (Suzhou) Co., Ltd, Dry Eye

NCT07739160
NCT07739160 — Beijing Suncadia Pharmaceuticals Co., Ltd, Acute Ischemic Stroke

NCT07739368
NCT07739368 — Jiangsu Aosaikang Pharmaceutical Co., Ltd., Iron Deficiency Anaemia

NCT07739888
NCT07739888 — Novartis Pharmaceuticals, Atrial Fibrillation (AF)

NCT07739186
NCT07739186 — Sichuan Baili Pharmaceutical Co., Ltd., Non-squamous Non-small Cell Lung Cancer

Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions
NCT07738510 — Halia Therapeutics, Inc., Myelodysplastic Syndromes

NCT07738822
NCT07738822 — Cullinan Therapeutics Inc., Immune Thrombocytopenia (ITP)

NCT07740512
NCT07740512 — Polaryx Therapeutics, Inc., Lysosomal Storage Disorders

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
NCT07738341 — Eddingpharm (Zhuhai) Co., Ltd., Breast Cancer (Locally Advanced or Metastatic)

A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
NCT07739199 — Sichuan Baili Pharmaceutical Co., Ltd., Squamous Non-small-cell Lung Cancer

NCT07738679
NCT07738679 — Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Advanced Solid Tumors

ATR 1072 in Participants With PRKAG2 Syndrome
NCT07738107 — Atrium Therapeutics, Cardiac Glycogenosis

NCT05665699
NCT05665699 — InventisBio Co., Ltd, Gout

NCT06927986
NCT06927986 — CSPC Megalith Biopharmaceutical Co.,Ltd., EGFR-mutated Locally Advanced or Metastatic NSCLC

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771 — MediLink Therapeutics (Suzhou) Co., Ltd., Locally Advanced or Metastatic Breast Cancer

NCT03451916
NCT03451916 — Pluristem Ltd., Hip Fracture

NCT05297045
NCT05297045 — Regor Pharmaceuticals Inc., Type 2 Diabetes Mellitus

NCT06708637
NCT06708637 — Formycon AG, Age-Related Macular Degeneration

NCT04911751
NCT04911751 — KoBioLabs, Psoriatic Plaque

NCT06154304
NCT06154304 — Cipla Ltd., Bronchial Asthma

NCT04474470
NCT04474470 — TyrNovo Ltd., Solid Tumor, Adult

NCT04852172
NCT04852172 — Asklepion Pharmaceuticals, LLC, Acute Vaso Occlusive Crisis (VOC)

NCT04686175
NCT04686175 — Inozyme Pharma, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

NCT03315182
NCT03315182 — Abeona Therapeutics, Inc, Mucopolysaccharidosis Type 3 B

NCT05177107
NCT05177107 — Adaptive Phage Therapeutics, Inc., Osteomyelitis

NCT05441826
NCT05441826 — Tenet Medicines, Minimal Change Disease

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
NCT06039449 — Invivyd, Inc., COVID-19

NCT04890106
NCT04890106 — Mankind Pharma Limited, Glaucoma, Open-Angle

NCT03942419
NCT03942419 — Eyenovia Inc., Myopia

NCT06126653
NCT06126653 — Aardvark Therapeutics, Inc., Autism Spectrum Disorder

NCT04219982
NCT04219982 — Repurposed Therapeutics, Inc., Motion Sickness

NCT02106650
NCT02106650 — Acrotech Biopharma Inc., Relapsed Peripheral T-Cell Lymphoma

NCT04830124
NCT04830124 — Mural Oncology, Inc, Cutaneous Melanoma

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637 — AstraZeneca, Newly Diagnosed Multiple Myeloma (NDMM)

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →